January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Six Icon Pipeline Six Header 

Cambridge Healthtech Institute’s 7th Annual
Protein Purification and Recovery
Streamlining Processes
January 21-22, 2015

The Protein Purification and Recovery conference explores how experts are innovating processes to achieve purity, and provides an overview of the current tactics and technologies for optimizing protein purification in the effort to reach consistency and quality. Case studies will be presented that illustrate the tenacity needed to maximize purity and yield, while minimizing purification steps. The agenda addresses process development and issues of scale, along with purifying challenging proteins, such as membrane proteins. The meeting also addresses purification of proteins in different expression systems, including mammalian, bacterial and insect cells.

Day 1 | Day 2 | Download Brochure | Speaker Biographies 

Final Agenda


1:30 pm Conference Registration

BUZZ Sessions png

2:00 BuzZ Session A

3:00 Refreshment Break in the Exhibit Hall with Poster Awards

3:45 BuzZ Session B
(More Details >>)

4:30-5:00 Short Course Registration

5:00-8:00 Dinner Short Courses More Details >> 


7:30 am Conference Registration and Morning Coffee

Purifying Membrane Proteins

8:15 Chairperson’s Opening Remarks

William Gillette, Ph.D., Senior Scientist, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research

Keynote Presentation

8:20 The Distinct Issues of Membrane Proteins versus Soluble Proteins

Robert StroudRobert Stroud, Ph.D., Professor, Biochemistry/Biophysics and Pharmaceutical Chemistry; Director, Membrane Protein Expression Center, University of California at San Francisco (UCSF)

Membrane proteins present distinct issues versus soluble proteins; pure, homogeneous and stable in solution. Eukaryotic proteins need expression in eukaryotic cells. These include yeast, and insect cells. Human proteins, to be expressed for antibody preparation, require proper tailoring and glycosylation; and can often be achieved only in human cells. Antibody partners can be the basis for proof of principle therapeutics, and for helping to purify, assay, and validate membrane proteins’ mechanisms.

9:00 Expression of Transmembrane Proteins in Yeast for Genetic, Biochemical and Structural Studies

 Mark E. DumontMark E. Dumont, Ph.D., Professor, Biochemistry and Biophysics, University of Rochester Medical Center

The difficulty of expression, solubilization, and purification of transmembrane proteins, particularly those from eukaryotes, constitutes a significant barrier to understanding their mechanisms. The use of a system based on expression of membrane proteins from various sources in baker’s yeast has allowed the use of genetic approaches for functional characterization and stabilization of expressed proteins, while facilitating purification of transmembrane enzymes, transporters, and receptors for biochemical studies and x-ray crystallographic structure determination.

9:30 Overproduction and Functional Characterization of Purified Equilibrative Nucleoside Transporters

Franklin A. HaysFranklin A. Hays, Ph.D., Assistant Professor, Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center

The Solute Carrier Superfamily proteins constitute a functionally and structurally diverse family in eukaryotic membrane proteomes and are associated with modulating efficacy for an equally broad range of human therapeutics. Our recent focus is on defining the molecular basis for Equilibrative Nucleoside Transporter (ENT) inhibition, transport, and substrate recognition. ENTs have only been identified in eukaryotic organisms and have proven recalcitrant to overexpression and functional characterization in purified form - this despite the fact that they directly bind or transport over 25 FDA approved therapeutics. We have developed an optimized pipeline for the production of active, pure, eukaryotic ENTs and have used this system to obtain novel insights into the transport characteristics of the only identified ENT protein from Saccharomyces cerevisiae named Function Unknown Now 26 (FUN26). This talk will focus on our efforts to overproduce, purify, solubilize, and reconstitute functional ENT proteins along with novel insights into ENT transport properties.   

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

10:50 GPCR Purification: Protein Engineering and Process Optimisation are Key Elements for Successful GPCR Crystallisation

 Markus KoglinMarkus Koglin, Ph.D., Associate Director, Protein Engineering, Heptares Therapeutics

The generation of Stabilised G-protein Coupled Receptors (StaRs) has opened new routes in the purification procedures for GPCRs. Here we demonstrate that protein quality is drastically improved with increasing thermostability. StaR generation alone normally does not provide suitable material for crystallisation. The combination of StaR technology, systematic construct design, and careful optimisation of the purification process delivers a powerful approach to generate protein with suitable crystallisation qualities.

11:20 Strategies for Detergent Stabilization and Large-Scale Affinity Purification of the Functional G Protein-Coupled Receptors

Alexei YeliseevAlexei Yeliseev, Ph.D., Staff Scientist, Group Leader, LMBB, NIAAA, National Institutes of Health (NIH)

Human cannabinoid receptor CB2, a G protein-coupled receptor involved in regulation of immune response, is an important target for pharmaceutical drug development. For high resolution structural studies, milligram quantities of pure, homogenous and functional protein are required. We expressed the functional CB2 receptor in E. coli, and optimized its purification by tandem affinity chromatography. An efficient strategy for stabilization of the receptor in detergent micelles and reconstituted into lipid bilayers was developed.

11:50 Overcoming Difficult to Express Proteins: Cell-Free Additives for Solubilizing and Characterizing Membrane Proteins

Matthew ColemanMatthew Coleman, Ph.D., Deputy Group Leader, Molecular Toxicology, Lawrence Livermore National Laboratory; Senior Scientist, University of California at Davis

We have developed cell-free methods for producing membrane proteins, which are inherently difficult to obtain. These include nanolipoprotein particles (NLPs), telodendrimers, which can be combined with NLPs or lipids, and amphipathic peptides. I will further discuss how we use the three different additives and their ability to support membrane protein solubility as well as function. These processes are easily adapted to high-throughput technologies for feeding the membrane structural biology pipeline.

12:20 pm High Throughput Strategies for MAB and FAB Development

Leticia Reyes-Regis, Ph.D., Senior Staff Scientist, Scientific Laboratory Services Department, Pall Life Sciences

Developing a purification process using conventional methods is less and less compatible with biopharm industry challenges in terms of timelines and cost constraints. High Throughput Process Development (HTPD) for screening chromatography sorbents and multiple process conditions, based on a Design of Experiment (DoE) approach, has become a standard that enables saving time and sample, while improving process efficiency. We will discuss mAb and Fab purification strategies leading to a three-step process set-up within 12 days.

12:50 Session Break 

1:00 Luncheon Presentation I: Accurately Assessing Comparibility of Biosimilar Interferon From Refolding to Polishing During Process Development

Belcher_PaulPaul Belcher, Ph.D., Market Development Leader, GE Healthcare Life Sciences

Developers of biosimilars use an array of biomolecular characterization methods to prove that their processes are well understood, robust, and controlled. Extensive analytical studies including comparative physicochemical and functional studies are needed to confirm similarity. This talk will describe a process for HTPD of IFNα-2a, compared throughout the development process with a market available reference molecule. The focus is on the use of Biacore™ T200 and Amersham™ WB system for accurate comparability studies during this development.


Purifying Antibodies

2:00 Chairperson’s Remarks

Matthew Coleman, Ph.D., Deputy Group Leader, Molecular Toxicology, Lawrence Livermore National Laboratory, and Senior Scientist, University of California at Davis

2:05 Resolving Protein Purification Challenges for Therapeutic Antibody Development

Erin Christensen, MBA, Research Associate, Protein Chemistry,Genentech, Inc. -- A Member of the Roche Group

Purification technology is fundamental in antibody drug discovery. Maintaining biological and biophysical features of antigens is critical to generate antibodies with high diversity and specificity. Various antigen forms and orthologs are required for antibody screening and cross-species affinity. With increasing numbers of new formats of antibody fragments as therapeutic proteins, there are more technical demands in purification and characterization. This talk will present case examples in dealing with target-specific challenges.

2:35 Development of an Industrially Relevant DSP Platform Process for a Bispecific Antibody, the κλ-Body

Jean-François DepoisierJean-François Depoisier, Head, Downstream Processing Unit, NovImmune SA

In order to exploit novel mechanisms of action and achieve superior clinical efficacy, NovImmune has developed a novel bispecific antibody format, the κλ-body that has a molecular structure identical to a fully human monoclonal antibodies. The talk will address the challenges in developing an industrially relevant purification process for this innovative bispecific antibody format. The strategy for identifying optimal work space based on a broad range scanning of process parameters and novel purification technologies will be presented.

3:05 BEAT Bispecific Antibody: Development of a Process with a Platform Approach

Sonia LetestuSonia Letestu, Process Development Engineer, DSP, Glenmark Pharmaceuticals S.A.

The BEAT® is a novel bispecific antibody techonology developed by Glenmark Pharmaceuticals. The scFv-FAB BEAT® format is a combination of a Fab arm and an ScFv arm with a fully functional Fc part, conserving key IgG properties such as thermostability, the potential for effector function and antibody-like pharmacokinetics. The presentation will present a new Bispecific technology specically engineered in order to allow an efficient impurity removal in one single step.

3:35 A New Alkali Stable Adsorbent for Antibody Purification

Burton_StevenSteve Burton, Ph.D., CEO, ProMetic BioSciences Ltd.

A small synthetic ligand that is alkaline stable has been designed and developed for the affinity purification of monoclonal antibodies. Data presented will demonstrate that the adsorbent, comprised of a synthetic ligand immobilised onto an agarose base matrix, performs comparably to the leading Protein A products in terms of binding capacity, recovery and purity.


ChromaCon3:50 A Step Change in Protein Purification

Bavand_MichaelMichael Bavand, Ph.D., CEO, ChromaCon AG

Twin-column protein purification for mAb platform processes enable significant cost savings and increased processing speed. Contichrom CUBE equipment is designed as a modular lab-scale system to run batch, cyclic and continuous processes that can be seamlessly scaled up to GMP pilot /process scale using LEWA’s EcoPrime Twin LPLC system.

4:05 Refreshment Break

4:30 Plenary Keynote Session

From Yeast to the Brain: Advances in Proteomics (More Details >>

John YatesJohn R. Yates, Ph.D., Ernest W. Hahn Professor, Chemical Physiology and Molecular and Cellular Neurobiology, The Scripps Research Institute


5:30-7:00 Reception in the Exhibit Hall with Poster Viewing

Day 1 | Day 2 | Download Brochure | Speaker Biographies